Oxaliplatin: a review in the era of molecularly targeted therapy - Wikidata - awgldk - TriplyDB

Oxaliplatin: a review in the era of molecularly targeted therapy

Oxaliplatin: a review in the era of molecularly targeted therapy

http://www.wikidata.org/entity/Q34541434

about

Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab.RAB8 enhances TMEM205-mediated cisplatin resistance.Gene signatures of drug resistance predict patient survival in colorectal cancer Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer Antimetabolite Treatment for Pancreatic Cancer.β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event.Important molecular genetic markers of colorectal cancer.Cucurbit[7]uril containers for targeted delivery of oxaliplatin to cancer cells Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer.BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice.Adjuvant therapy for early colon cancer: current status.Oxaliplatin: a review of approved uses.Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.Oxaliplatin for the treatment of ovarian cancer.MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.Current and advancing treatments for metastatic colorectal cancer.A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols.Apoptotic Process Induced by Oxaliplatin in Rat Hippocampus Causes Memory Impairment.Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.cis-[Pt(II) (1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)], a water-soluble, oxalate-free and stable analogue of oxaliplatin: synthesis, characterization, and biological evaluations.The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.Oxaliplatin-induced neuropathy in colorectal cancer Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.Effects of Oxaliplatin Treatment on the Enteric Glial Cells and Neurons in the Mouse Ileum.QT interval prolongation and torsades de pointes with oxaliplatin.Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity.Preventive Effects of Bee Venom Derived Phospholipase A₂ on Oxaliplatin-Induced Neuropathic Pain in Mice.Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.

P2860

Q26749037-A6B72DA7-5A46-4CF8-9A2F-BE8F6F77BF48 Q28082382-C2F31897-E269-4A3F-9D0F-4CF1FE98B85A Q33427607-8EAF764D-D44C-49D6-AFAC-5F99F8A3EB71 Q33744706-A07E92F5-3513-494E-BDDF-0242CB21DCF7 Q34049929-C348DE8C-92A6-45C0-9C8E-175C28BCACCA Q34221132-104247A9-A02C-4044-B42A-37B386BBBD8B Q35237150-F7E31045-EC7F-42CE-BF8E-B5A08B408522 Q35742126-3E5C8FE0-DD01-452E-BBEF-CD620CE5E168 Q35826334-759B692B-41D8-459A-9094-EB0DE365A537 Q35921211-007C83D5-C395-41A3-AB39-450FAADFF460 Q36220792-4F937D74-C2AE-4506-A5E0-2858C8EC46B1 Q36261283-4A0B1016-156E-48F8-861C-7B1E43E483A7 Q36421186-73292150-0FA0-4A70-BBAB-8B5F65C3127D Q37474599-28D62340-65E5-4684-8E76-855F113BF692 Q37513908-F71A995B-A94E-41F4-A51D-9F71300B8668 Q37619856-717B02CF-BA7D-46B9-8CBB-6E4A25C7873E Q37638514-0D3AFE05-D109-470F-9365-21B1EA4C736E Q37706601-BDCD47F2-7F17-42FE-8BC4-31D2124A5F76 Q37742823-EB389611-BFBB-4691-9978-7B7A27D86CBD Q37956401-203013C7-EC2F-4837-95EA-87150B11BACC Q37965616-3A1D03F4-D93D-4F28-B448-3E7DD35EE074 Q38287054-776E348A-4248-4649-BB22-7C0B0DB7CE48 Q38540596-F7910831-A296-41B0-A86D-F79E62C2362A Q38552402-FBC699CC-41CE-4C9E-9D9D-77A8989C5783 Q38628257-3B831590-9DB4-471A-A5FE-AC8E7EBDE8D6 Q38667417-7E5E207D-AC58-4F55-A01D-22DF897CC118 Q38761720-5AF03CCA-5F3C-4586-A068-1687FC7F969E Q38765958-E6E56385-B4B6-4AAF-BE86-8384A2AB79D4 Q38984857-A8323D8B-110F-4235-BF4F-76B736B48D70 Q39130757-DFB57A5F-A6BE-460D-9B1F-809B5EECC43A Q39233316-1FAC326B-BCBA-46F6-9D9B-C5178DE9EC67 Q39803653-9B22FDA5-B23A-4DFE-9004-CA291EDFE288 Q40578433-0701EEF2-6855-4B1B-999F-3E95C0956906 Q40983000-952C0083-2A48-4B78-9762-E4BD6B245773 Q42166906-A7486670-6E78-4B8E-948B-98690F8F842F Q42361420-955DCED4-07FC-471A-A635-F154758F3527 Q43066432-2D2560D7-FD91-43D2-9410-005F9BF16092 Q44242635-859DC4EE-4BF3-409D-B5BF-781095D4FE8F Q45243526-6C45BB16-FCDF-4954-B46E-5C01A7BF8251 Q46417081-3A45D370-6362-4B8E-85A5-A58136A74604

P2860

Oxaliplatin: a review in the era of molecularly targeted therapy

http://www.wikidata.org/entity/Q34541434

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Oxaliplatin: a review in the era of molecularly targeted therapy

@ast

Oxaliplatin: a review in the era of molecularly targeted therapy

@en

Oxaliplatin: a review in the era of molecularly targeted therapy

@nl

type

label

Oxaliplatin: a review in the era of molecularly targeted therapy

@ast

Oxaliplatin: a review in the era of molecularly targeted therapy

@en

Oxaliplatin: a review in the era of molecularly targeted therapy

@nl

prefLabel

Oxaliplatin: a review in the era of molecularly targeted therapy

@ast

Oxaliplatin: a review in the era of molecularly targeted therapy

@en

Oxaliplatin: a review in the era of molecularly targeted therapy

@nl

P1433

Q34541434-1E32E6DB-4E52-4E90-B26F-DD44AB91DA78

P1476

Q34541434-67EE7F29-A49C-4C75-BE4D-E5F28D004021

P2093

Q34541434-C7843534-AE66-480C-81D2-8A6C16B69A4A

Q34541434-DC6F8392-4278-457A-8415-0A115152E7B6

P2860

Q34541434-02373CDD-C716-45D5-AE7C-A4E5AC5F3A5C

Q34541434-04697BF6-F554-4EAA-8D89-542C12F81092

Q34541434-0D191215-CF0F-4D11-A758-2EC77E4BAAEE

Q34541434-0ED5F696-ACDB-45AC-AF9F-819DB597CD68

Q34541434-10C96CDF-6942-47B0-BF19-C58B57A62997

Q34541434-1D0E6045-E3B3-4C0A-89B4-6CD84E8763CF

Q34541434-1FFE072C-6AB6-433F-90FE-9651EB7286B7

Q34541434-20D7A8F9-A718-4FF5-8C72-6BA39CDFDE34

Q34541434-21EBB430-BF15-4239-9892-8A9D5E275E6C

Q34541434-29218DAE-32AA-4A3F-B00C-DBF17BB89C94

P304

Q34541434-12BC76C3-23AD-45AF-81B4-28B3232E2201

P31

Q34541434-F15633B0-C17D-4AB3-B855-1964BFF8DF73

P356

Q34541434-45F33137-DCF4-4D64-B066-150BD18AE4B4

P433

Q34541434-D6420051-1222-464C-A37E-EF655331C9D7

P478

Q34541434-A8B1C872-AE5B-44C0-98A7-441BE462F58A

P577

Q34541434-EB654D50-8E0D-42B2-AAAF-7C017B43A59F

P5875

Q34541434-1D8EEA25-F75A-4259-820D-4FA8B5EEE97E

P698

Q34541434-FDFC5FDB-7609-46E5-AD58-CB499B77826F

P932

Q34541434-3D10907D-3499-4555-AF48-3D58843EDC71

P356

P1433

Current Oncology

P1476

Oxaliplatin: a review in the era of molecularly targeted therapy

@en

P2093

N Beauger

http://www.w3.org/2001/XMLSchema#string

T Alcindor

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis.

Long-term platinum retention after treatment with cisplatin and oxaliplatin.

Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.

Clinical pharmacokinetics of oxaliplatin: a critical review.

P304

18-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.V18I1.708

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49845628

http://www.w3.org/2001/XMLSchema#string

P698

21331278

http://www.w3.org/2001/XMLSchema#string

P932

3031353

http://www.w3.org/2001/XMLSchema#string